Hims & Hers planning to sell compounded peptides
Hims & Hers Health is planning to sell compounded peptides, the company said in a Monday earnings call. The company’s CEO, Andrew Dudum, said in the earnings call that it was “currently developing a best-in-class peptides experience, including U.S.
Reported by 1 outlet — The Hill. See all sources ↓
Hims & Hers Health is planning to sell compounded peptides, the company said in a Monday earnings call. The company’s CEO, Andrew Dudum, said in the earnings call that it was “currently developing a best-in-class peptides experience, including U.S. manufactured products, clinical-led guidance, and ongoing blood testing.” Dudum said in the call that the company...
Read the full report at The Hill ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- Hims & Hers Health is planning to sell compounded peptides, the company said in a Monday earnings call. The company’s CEO, Andrew Dudum, said in the earnings call that it was “currently developing a best-in-class peptides experience, including U.S.
- How widely is it covered?
- 1 outlet, average source rating 7.0/10.
- When was it last updated?
- 9m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Hims & Hers planning to sell compounded peptides
Sources1TypeCoverageThe Hill